Eli Lilly's Taltz shows superiority versus Johnson & Johnson's Tremfya in psoriasis study

Eli Lilly announced that the IL-17A inhibitor Taltz (ixekizumab) demonstrated superiority versus Johnson & Johnson's IL-23/p19 inhibitor Tremfya (guselkumab) in a study of patients with moderate-to-severe plaque psoriasis. "We're pleased to see that Taltz helped more people achieve 100% skin clearance compared to Tremfya at week 12," remarked Lotus Mallbris, vice president of immunology development at Eli Lilly.

The Phase IV IXORA-R study randomised 1027 patients with moderate-to-severe plaque psoriasis to receive Taltz or Tremfya for a total of 24 weeks, with the primary analysis conducted at 12 weeks. Eli Lilly said that the trial met its primary endpoint by demonstrating superiority in the proportion of patients achieving complete skin clearance compared to Tremfya as measured by the Psoriasis Area Severity Index (PASI) 100 score.

The drugmaker added that Taltz also met all major secondary goals up to week 12, which include superiority over Tremfya in the proportion of patients achieving PASI 75 at week two, PASI 90 at weeks four and eight, PASI 100 at weeks four and eight, static Physician's Global Assessment (sPGA) 0 at week 12 and PASI 50 at week one. Eli Lilly indicated that results on the remaining key secondary endpoint of proportion of patients achieving PASI 100 at 24 weeks will be available next year.

According to the company, the safety profile of Taltz in the study was consistent with previously reported results, while no new safety signals were detected. Eli Lilly plans to submit detailed data from the study for presentation at a scientific meeting.

Taltz, which generated sales of $353.8 million in the second quarter, is currently approved to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The therapy is also authorised for the treatment of adults with active psoriatic arthritis, with Eli Lilly announcing last year that the drug showed superiority versus AbbVie's Humira (adalimumab) in this indication.

For related analysis, see Physician Survey Results: New psoriasis biologics come to the fore.

To read more Top Story articles, click here.